C WorldWide Group Holding A S lifted its position in shares of Insulet Corporation (NASDAQ:PODD – Free Report) by 17.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 99,908 shares of the medical instruments supplier’s stock after buying an additional 15,000 shares during the quarter. C WorldWide Group Holding A S’s holdings in Insulet were worth $20,965,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in PODD. Larson Financial Group LLC raised its holdings in shares of Insulet by 114.6% in the fourth quarter. Larson Financial Group LLC now owns 88 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 47 shares in the last quarter. University of Texas Texas AM Investment Management Co. bought a new position in Insulet during the 4th quarter worth about $26,000. Elyxium Wealth LLC purchased a new position in Insulet during the 4th quarter valued at about $28,000. DV Equities LLC purchased a new position in Insulet during the 4th quarter valued at about $28,000. Finally, MV Capital Management Inc. bought a new stake in shares of Insulet in the 4th quarter valued at about $29,000.
Trending Headlines about Insulet
Here are the key news stories impacting Insulet this week:
- Neutral Sentiment: Multiple law firms issued reminders and investor alerts about a securities class action against Insulet, with lead-plaintiff deadlines set for August 31, 2026. These notices generally keep the stock in the spotlight but do not by themselves change the underlying case. Article link
- Neutral Sentiment: Another law firm announced that a class action lawsuit has been filed against Insulet and certain officers on behalf of investors who bought shares during the alleged class period, reinforcing concerns about legal overhang for the company. Article link
- Neutral Sentiment: Prior reporting cited allegations that two Omnipod corrections may have exposed broader quality-control issues and contributed to a sharp earlier selloff, which helps explain why litigation-related headlines remain a focus for traders. Article link
Insulet Trading Up 3.2%
Insulet (NASDAQ:PODD – Get Free Report) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.19 by $0.23. The business had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a net margin of 10.44% and a return on equity of 26.87%. The business’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same period in the previous year, the company earned $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. As a group, sell-side analysts anticipate that Insulet Corporation will post 6.45 earnings per share for the current fiscal year.
Insider Buying and Selling at Insulet
In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the company’s stock in a transaction that occurred on Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director directly owned 9,041 shares in the company, valued at $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.36% of the stock is owned by insiders.
Wall Street Analysts Forecast Growth
A number of research firms have recently issued reports on PODD. BTIG Research dropped their price objective on shares of Insulet from $260.00 to $235.00 and set a “buy” rating on the stock in a research note on Tuesday, May 26th. JPMorgan Chase & Co. reduced their price objective on shares of Insulet from $340.00 to $275.00 and set an “overweight” rating for the company in a research note on Thursday, May 7th. UBS Group set a $219.00 target price on Insulet in a research report on Thursday, June 11th. Sanford C. Bernstein cut their price target on Insulet from $330.00 to $200.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Finally, Royal Bank Of Canada cut their price target on Insulet from $280.00 to $245.00 and set an “outperform” rating on the stock in a report on Monday. Twenty-two investment analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Insulet currently has an average rating of “Moderate Buy” and a consensus price target of $235.25.
View Our Latest Research Report on Insulet
Insulet Company Profile
Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.
The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.
Featured Articles
- Five stocks we like better than Insulet
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
Want to see what other hedge funds are holding PODD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insulet Corporation (NASDAQ:PODD – Free Report).
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.png){kind=logo}
